<!doctype html>
<html lang="en">

<head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta http-equiv="x-ua-compatible" content="ie=edge">
    <meta name="content" description="">

    <!--google fonts-->
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400,600,700|Roboto:400,500,700,900" rel="stylesheet">

    <!--favicon here-->
    <link rel="icon" href="img/favicon.ico" type="image/ico" sizes="16x16">


    <!--all external libraries goes here-->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/font-awesome.min.css">

    <link rel="stylesheet" href="css/slick.css">
    <link rel="stylesheet" href="css/slick-theme.css">

    <!--custom css-->
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/responsive.css">


    <!--place scripts after stylesheets-->
    <!--highchart dependencies and libs-->

    <script src="js/jquery.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery-circle-progress/1.2.2/circle-progress.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery-cookie/1.4.1/jquery.cookie.min.js"></script>

    <!-- Google Tag Manager -->
    <!--    <script>(function (w, d, s, l, i) {-->
    <!--            w[l] = w[l] || []; w[l].push({-->
    <!--                'gtm.start':-->
    <!--                    new Date().getTime(), event: 'gtm.js'-->
    <!--            }); var f = d.getElementsByTagName(s)[0],-->
    <!--                j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =-->
    <!--                    'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);-->
    <!--        })(window, document, 'script', 'dataLayer', 'GTM-N3X92QM');</script>-->
    <!-- End Google Tag Manager -->
    <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
          new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
      j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
      'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-KDCFGCZ');</script>
    <!-- End Google Tag Manager -->Œ
    <title>Keytruda RCC</title>
    <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
          new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
      j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
      'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-KT8KRGD');</script>
    <!-- End Google Tag Manager -->
</head>

<body>
<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KDCFGCZ"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->
<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KT8KRGD"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
    <span class="scroller-fixed-height">

    </span>

    <div id="linedraw-wrapper">
        <div class="progress-container">
            <div class="progress-bar" id="myBar"></div>
        </div>
    </div>
    <!--==========================site header starts here=====================================-->
    <header class="header w-100 fixed-top" id="siteHeader">
        <div class="top-header bg-white">
            <div class="container">
                <div class="row">

                    <div class="col-lg-6 col-md-5 text-left desktop-only">
                        <img src="img/logo.png" alt="Logo" class="img-fluid pointer"
                            onclick="window.location.href='index.html'">
                    </div>
                    <!--end logo holder-->
                    <div class="col-lg-6 col-md-5 mobilelogo">
                        <img src="img/Keytruda-logo.png" alt="Logo" class="pointer"
                            onclick="window.location.href='index.html'">
                    </div>
                    <!--end logo holder-->

                    <div class="col-lg-6 col-md-7 text-right my-auto">
                        <ul class="list-unstyled list-inline mb-0">

                            <li class="list-inline-item">
                                <a href="#"
                                    target="_blank"><img src="img/publication_icon.png" alt="publication-icon" class="img-fluid">
                                    KEYNOTE-426 publication</a>
                                </li>

                            <li class="list-inline-item">
                                <a href="https://www.merck.ca/confirm-monograph.xhtml?file=KEYTRUDA-PM_E.pdf"
                                    target="_blank"><img src="img/header-icon1.png" alt="header-icon" class="img-fluid">
                                    Product Monograph</a>
                                </li>

                            <li class="list-inline-item"><a href="#" data-toggle="modal"
                                    data-target="#safety-popup"><img src="img/header-icon2.png" alt="header-icon">
                                    Safety Information</a></li>

                            <li class="french-button">
                                <a href="fr/index.html">Français</a> 
                            </li>
                        </ul>
                    </div>
                    <!--end col md4-->
                </div>
                <!--end row-->
            </div>
            <!--end contianer-->
        </div>
        <!--end top header-->

        <div class="navigation back-primary">
            <div class="container">
                <nav class="navbar navbar-expand-md back-primary navbar-dark custom-navbar">

                    <div class="custom-navigation w-100">

                        <div class="d-flex justify-content-between align-items-center mobile-ipad-only-flex">
                            <img src="img/logo-white.png" alt="logo">
                            <i class="fas fa-bars" onclick="openNav()" class="mobile-ipad-only"></i>
                        </div>
                        <!--end mobile ipad only-->

                        <div id="mySidenav" class="sidenav mobile-ipad-only">
                            <a href="javascript:void(0)" class="closebtn" onclick="closeNav()">&times;</a>
                            <a href="#" id="#section-1" class="mobile-links">KEYTRUDA Patient Profiles</a>
                            <a href="#" id="#section-2" class="mobile-links">Efficacy</a>
                            <a href="#" id="#section-3" class="mobile-links">Safety</a>
                            <a href="#" id="#section-4" class="mobile-links">Dosing</a>
                            <a href="#" id="#section-5" class="mobile-links">Contact us</a>
                        </div>
                        <!--end mobile navigation-->


                        <ul class="navbar-nav custom-nav desktop-only-flex nav-carousel-mobile">

                            <li class="nav-item">
                                <a class="nav-link scroll" href="#section-1"> <span><img src="img/melan-icon.png"
                                            alt="Keytruda experience"></span> KEYTRUDA<sup>&reg;</sup></a>
                            </li>

                            <li class="nav-item">
                                <a class="nav-link scroll" href="#section-action"> <span><img src="img/mechanism-action.png"
                                            alt="mechanism_action"></span> MEchanism of action</a>
                            </li>

                            <li class="nav-item">
                                <a class="nav-link scroll test-navver" href="#section-2"> <span><img
                                            src="img/nav-icon2.png" alt="Efficacy"></span> Efficacy</a>
                            </li>


                            <li class="nav-item">
                                <a class="nav-link scroll" href="#section-3"> <span><img src="img/nav-icon3.png"
                                            alt="safety"></span> Safety Profile</a>
                            </li>

                            <li class="nav-item">
                                <a class="nav-link scroll" href="#section-4"> <span><img src="img/nav-icon4.png"
                                            alt="Dosing"></span> Dosing</a>
                            </li>

                            <li class="nav-item">
                                <a class="nav-link scroll" href="#section-5"> <span><img src="img/nav-icon6.png"
                                            alt="Oncology Program"></span> Merck care<sup>TM</sup></a>
                            </li>
                            <li class="nav-item">
                                
                            </li>

                        </ul>
                        <!--end navbar nav-->
                        <button type="button" class="mobile_scroll_btn pn-Advancer_Left" id="pnAdvancerLeft">
                            <img src="img/left-arrow.png" alt="left-arrow">
                            </button>
                        <button type="button" class="mobile_scroll_btn pn-Advancer_Right" id="pnAdvancerRight">
                            <img src="img/right-arrow.png" alt="right-arrow">
                            </button>
                    </div>
                    <!--end collapse-->

                </nav>
                <!--end navigation-->
            </div>
            <!--end container-->
        </div>
        <!--end navigation-->
    </header>
    <!--end header-->
    <!--==========================site header starts here=====================================-->

    <!--==========================site main body starts here=====================================-->
    <main class="main-body w-100" id="siteBody">
        <!--section start-s here-->
        <section class="banner-section w-100 background-properties">

            <div class=" w-100">
                <div class="container banner_head">
                    <div class="row">
                        <div class="col-lg-6 col-md-9 col-12">
                            <div class="banner_box">
                                
                                <div class="banner-message banner_box_xs_hide">
                                    <h1 class="brand-color banner-heading font-weight-bold">KEYTRUDA<sup>®</sup>: New indication in advanced or metastatic renal cell carcinoma (RCC) in combination with axitinib, in adults with no prior systemic therapy for metastatic RCC</h1>
                                    <p class="text-lighter">The Kidney Cancer Research Network of Canada (KCRNC) recommends pembrolizumab + axitinib in the following patients with untreated, advanced clear-cell:<sup>2*</sup></p>
                                    <ul class="banner-icon-list">
                                        <li>
                                            <div class="left-icon-list">
                                                <img src="img/banner-list-icon1.png" alt="patients">
                                            </div>

                                            <div class="right-icon-list">
                                                <p><strong>Intermediate- or poor-risk patients</strong></p>
                                                <p>pembrolizumab + axitinib: Preferred therapy</p>
                                            </div>
                                        </li>

                                         <li>
                                            <div class="left-icon-list">
                                                <img src="img/banner-list-icon2.png" alt="patients" class="pl-3">
                                            </div>

                                            <div class="right-icon-list">
                                                <p><strong>Favourable-risk patients</strong></p>
                                                <p>pembrolizumab + axitinib: Preferred therapy</p>
                                            </div>
                                        </li>
                                    </ul>

                                  <div class="text-center">
                                       <a href="#" target="_blank" download="" class="download-button banner-btn btn button-second">
                                        Review the KCRNC Consensus Statement <img src="img/download_table.png" alt="download_table"> 
                                    </a>
                                  </div>
                                </div>
                                <!--end banner message-->
                            </div>
                        </div>
                        <!--end banner content col-->
                    </div>
                    <!--end row-->
                </div>
                <!--end container-->
            </div>
            <!--end banner content-->
        </section>
        <!--end banner section-->
        <!--secton ends here-->
        <div class="xs_visi_under_banner_txt">
        </div>
        <!--section start-s here-->
        <section class="subheading-section w-100 pt-5" id="section-1">
            <div class="container">
                <div class="row risk_of_death_sec border-bot">
                    <div class="col-md-12 col-lg-5 col-12">
                        <div class="subheading-left-section pr-lg-4 pr-md-0">
                            <h3 class="brand-color mb-3">KEYTRUDA<sup>&reg;</sup> and axitinib: Two different drug classes for the treatment of RCC <sup>1,3</sup></h3>

                        <!--mobile-->
                            <div class="risk_of_death_present campare_sec_present_button ">
                                <div class="box_bottom_img">
                                    <img src="img/bottom_green_box.png" alt="bottom_green_box">
                                </div>
                                <div class="present_box reduction-block mobile-reduction text-center">
                                    <img src="img/down-arrow.png" alt="down-arrow">

                                    <h2 class="mb-0 flex-column">
                                        <span class="f-big"> Demonstrated: 51% reduction</span>
                                        <span>
                                            <h6>in the risk of death vs. placebo+plat/pem</h6>

                                            <h6 class="inline">HR<sup>*</sup>=0.49 (95% CI: 0.38-0.64), p<sup>†</sup><0.00001 </h6> <h6 class="inline"> Patient deaths: 31% (KEYTRUDA) vs.
                                                    52% (placebo)
                                            </h6>
                                        </span>


                                    </h2>
                                </div>
                            </div>
                             <!--mobile-->

                            <a href="#down-keynote">
                                <div class="skip_keynote_mob">
                                    <p>Skip to KEYNOTE-189 study design
                                        <img src="img/skip-arrow.png" alt="down_arow">
                                    </p>
                                </div>
                            </a>

                        </div>
                        <!--end left section-->
                    </div>
                    <!--end col-->

                    <div class="col-md-12 col-lg-7 col-12">
                       <div class="block-subheading-right-wrapper">
                           <div class="info-block primary-green">
                               <h4>PD-1 receptor inhibitor</h4>
                               <p>KEYTRUDA<sup>&reg;</sup> (pembrolizumab)</p>
                           </div>
                            <div class="plus-holder">
                                <h1>+</h1>
                            </div>
                           <div class="info-block primary-blue">
                                <h4>VEGF receptor tyrosine kinase inhibitor</h4>
                               <p>axitinib</p>
                           </div>
                       </div>   
                       <p class="text-center gray-info-text">Clinical significance is unknown.</p>                  
                    </div>
                    <!--end col-->

                </div>
                <!--end row-->

                <div class="row subheading-bottom-new-section">
                    <div class="col-12 col-md-12 col-lg-9">
                        <h4>KEYTRUDA<sup>&reg;</sup> + axitinib: Demonstrated efficacy in the following 3 endpoints vs. sunitinib in the open-label KEYNOTE-426 study (first interim analysis)</h4>
                    </div>

                    <div class="col-12 col-md-12 col-lg-12 mt-4">
                         <div class="bar-section">
                            <div class="col-block">
                                <div class="content-text-block">
                                    <p class="col-header"><strong>Overall Survival (OS):<sup>†</sup></strong></p>
                                    <p>47% reduction in risk of death; HR<sup>‡</sup>=0.53 (95% CI: 0.38-0.74), p<sup>§</sup>=0.00005; Patient deaths: 14% (KEYTRUDA<sup>®</sup> + axitinib) vs. 23% (sunitinib)</p>
                                </div>

                                <div class="progress-bar-wrapper">
                                    <p>reduction in risk of death</p>
                                </div>
                            </div>

                            <div class="col-block">
                                <div class="content-text-block">
                                    <p class="col-header"><strong>Overall Response Rate (ORR):<sup>†</sup></strong></p>
                                    <p>59% (95% CI: 54, 64) KEYTRUDA<sup>®</sup> + axitinib vs. 36% (95% CI: 31, 40) sunitinib, p+<0.0001 (secondary endpoint)</p>
                                </div>

                                <div class="progress-bar-wrapper">
                                    <p>reduction in risk of death</p>
                                </div>
                            </div>

                            <div class="col-block">
                                <div class="content-text-block">
                                    <p class="col-header"><strong>Progression-Free Survival (PFS):<sup>†</sup></strong></p>
                                    <p>31% reduction in risk of progression of death; HR<sup>‡</sup>=0.69 (95% CI: 0.56, 0.84), p<sup>§</sup>=0.00012; Event rate: 42% (KEYTRUDA<sup>®</sup> + axitinib) vs. 50% (sunitinib)</p>
                                </div>

                                <div class="progress-bar-wrapper">
                                    <p>reduction in risk of death</p>
                                </div>
                            </div>
                            
                        </div>

                        <div class="bar-footer-content">
                            <p class="small gray-lighter-text">Adapted from the Product Monograph.<sup>1</sup></p>

                            <p class="ultra-small gray-lighter-text">CI=confidence interval; HR=hazard ratio; IMDC=International Metastatic RCC Database Consortium; PD-1=programmed cell death protein 1; VEGF=vascular endothelial growth factor</p>

                            <div class="footer-content-row">
                                <div class="footer-content-col">
                                    <p class="ultra-small gray-lighter-text">*Active surveillance can also be considered in selected patients with IMDC favourable-risk/intermediate-risk, with one risk factor, as some patients have slow-growing, low-volume, and/or asymptomatic disease</p>
                                    <p class="ultra-small gray-lighter-text">† OS and PFS were assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. </p>
                                </div>

                                <div class="footer-content-col">
                                    <p class="ultra-small gray-lighter-text">‡ Based on the stratified Cox proportional hazard model</p>
                                    <p class="ultra-small gray-lighter-text">§ Based on stratified log-rank test</p>
                                    <p class="ultra-small gray-lighter-text">¶ Based on patients with a best overall response as confirmed complete or partial response</p>
                                    <p class="ultra-small gray-lighter-text">+ Based on Miettinen and Nurminen method stratified by IMDC risk group and geographic region </p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="row">
                    <div class="col-12">
                        <a href="#down-keynote" class="skit-link">
                            <div class="skit_arrow arrow-shifted arrow-modified">
                                <p class="">Skip to KEYNOTE-426 study design</p>
                                <img src="img/skip-arrow_white.png" alt="skip-arrow">
                            </div>
                        </a>

                    </div>
                </div>

            </div>
            <!--end container-->

        </section>
        <!--end content section-->
        <!--secton ends here-->

        <!--section starts here-->
        <section id="section-action"
            class="page-banner-content keytruda-experience w-100 background-properties back-effect line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-white">
                    <div class="row">
                        <div class="col-lg-6 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle" id="lineStarter"></span>
                                Mechanism of Action</h2>
                            <p class="page-lead">This section outlines the two mechanisms of action for KEYTRUDA<sup>®</sup> and axitinib.<sup>1,3*</sup></p>
                        </div>
                        <!--end col md-->

                        <div class="col-lg-4 offset-lg-1 content-right col-md-5 offset-md-0">
                        </div>
                        <!--end banner accordion section-->
                    </div>
                    <!--end row-->
                </div>
                <!--end container-->
            </div>
            <!--end section content holder-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 patient line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-12 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Is
                            KEYTRUDA<sup>&reg;</sup> and axitinib
                        </h2>

                    </div>
                    <!--end col-->
                </div>
                <!--end row-->
                <!--second row repeated with first row-->
                <div class="row">
                    <div class="col-md-12 col-lg-10 mx-auto col-12 mt-4">

                        <div class="custom-card-wrapper">

                            <div class="card card-primary-custom card-primary-green">

                              <div class="card-header">
                                  <h5>PD-1 receptor <br>inhibitor</h5>
                                  <p>KEYTRUDA<sup>®</sup> (pembrolizumab)</p>
                              </div>

                              <div class="card-body">
                                <p class="text-center mb-0">Supporting anti-tumour activity</p>
                                <img src="img/card-1.png" alt="PD-1 receptor" class="img-fluid">
                                   <ul class="custom_dots">
                                       <li>KEYTRUDA<sup>®</sup> binds to the PD-1 receptor, which exerts dual ligand blockade of PD-L1 and PD-L2 on antigen-presenting or tumour cells.</li>
                                       <li>By inhibiting the PD-1 receptor, KEYTRUDA<sup>®</sup> reactivates tumour-specific cytotoxic T lymphocytes in the tumour microenvironment and reactivates anti-tumour immunity.</li>
                                   </ul>
                              </div>
                            </div><!--end card-->

                            <div class="custom-card-plus-wrapper">
                                <h1>+</h1>
                            </div>

                            <div class="card card-primary-custom card-primary-blue">
                               <div class="card-header">
                                  <h5>VEGF receptor tyrosine kinase inhibitor</h5>
                                  <p>axitinib</p>
                              </div>

                              <div class="card-body">
                                <p class="text-center mb-0">Promoting angiogenesis</p>
                                <img src="img/card-2.png" alt="Blood vessel" class="img-fluid">
                                   <ul class="custom_dots">
                                       <li>Axitinib has been shown to inhibit tyrosine kinase VEGF receptor (VEGFR)-1, VEGFR-2, and VEGFR-3.</li>
                                       <li>These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer.</li>
                                   </ul>
                              </div>
                            </div>



                        </div><!--end card custom wrapper-->

                       <div class="bar-footer-content">
                            <p class="small gray-lighter-text mb-0">Adapted from the respective Product Monographs.<sup>1,3</sup></p>
                            <p class="small gray-lighter-text"><strong>* Clinical significance is unknown</strong></p>

                            <p class="ultra-small gray-lighter-text">PD-L1=programmed death ligand 1; PD-L2=programmed death ligand 2</p>
                        </div>
                        <h4 class="text-bot-card">KEYTRUDA is indicated in combination with axitinib</h4>


                    </div>
                </div>

            </div>

            </div>
            <!--end container-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section id="section-2"
            class="page-banner-content w-100 background-properties back-effect light efficacy line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-white py-5 py-100-fixer">
                    <div class="row">
                        <div class="col-lg-7 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header efficacy-heading-line"><span class="pulsating-circle"></span>
                                Efficacy</h2>
                            <p class="page-lead">Consider KEYTRUDA<sup>®</sup> + axitinib as a treatment option for your patients with advanced or metastatic RCC with no prior systemic therapy for mRCC</p><br>
                            <p class="page-lead">In this section, the design of the pivotal study KEYNOTE-426 is presented. Baseline characteristics that describe the study population are outlined. The efficacy data for 3 endpoints (OS, PFS, ORR) are also presented.</p>
                        </div>
                        <!--end col md-->

                        <div
                            class="col-lg-4 col-md-6 offset-lg-1 offset-md-0 content-right mt-md-3 mt-lg-0 mt-sm-0 mt-0">
                            <ul class="banner-section-listing">
                                <li><a href="#down-keynote">Study Design</a></li>
                                <li><a href="#baseline-link">Baseline Characteristics</a></li>
                                <li><a href="#overall-link">Overall Survival data</a></li>
                                <li><a href="#progression-link">Progression-Free Survival data</a></li>
                                <li><a href="#objective-response-link">Objective Response Rate data</a>
                                </li>
                            </ul>
                            <!--end banner section listing-->
                        </div>
                        <!--end banner accordion section-->
                        <span id="down-keynote" class="link-grabber"></span>
                    </div>
                    <!--end row-->

                </div>
                <!--end container-->

            </div>
            <!--end section content holder-->

        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 keynote line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-9 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span>Study Design<sup>1</sup></h2> 
                        <p class="common-text">KEYNOTE-426 is the pivotal phase 3, multicentre, randomized, open-label trial that evaluated the efficacy and safety profile of KEYTRUDA<sup>®</sup>   in combination with axitinib vs. sunitinib in patients with advanced or metastatic RCC with clear cell component.<sup>1</sup></p>
                    </div>
                    <!--end col-->
                </div>
                <!--end row-->
                
                <!--mobile-->
                <div class="row my-3 mobile-ipad-only">
                    <div class="col-12">
                        <div class="slider-mobile-only">

                            <div class="step-m-1">
                                <div class="steps mb-3">
                                    <span>1</span>
                                    <h5>Inclusion Criteria</h5>
                                </div>
                                <!--end steps-->

                                <div class="step-1 align-items-center d-flex py-2 px-3">

                                    <ul class="step-1-list list-unstyled">
                                        <li>Metastatic non-squamous NSCLC</li>
                                        <li>No prior systemic treatment for mNSCLC</li>
                                        <li>No EGFR or ALK genomic tumour aberrations<sup>1</sup></li>
                                    </ul>
                                    <!--end step1 listing-->
                                </div>
                                <!--end step1-->
                            </div>
                            <!--end content-->

                            <div class="two-stepper-holder">
                                <div class="steps mb-3">
                                    <span>2</span>
                                    <h5>Study Arms</h5>
                                </div>
                                <!--end steps-->

                                <div class="left-step-section text-center">
                                    <img src="img/mobile-circle-data.png" alt="chart" class="img-fluid">
                                </div>
                                <!--end left step section-->

                                <div class="step-2 d-flex  align-items-center py-4">

                                    <div class="right-step-section">
                                        <div class="top-block">
                                            <h4 class="secondary-page-header text-center">KEYTRUDA<sup>&reg;</sup></h4>
                                            <p class="primary-block common-text-block back-primary text-white">
                                                KEYTRUDA<sup>&reg;</sup> 200 mg + pemetrexed 500 mg/m<sup>2</sup> +
                                                investigator’s choice of cisplatin 75 mg/m<sup>2</sup> or carboplatin
                                                area under the curve (AUC) 5 mg/mL/min IV every 3 weeks for 4 cycles
                                                followed by KEYTRUDA<sup>&reg;</sup> 200 mg + pemetrexed 500
                                                mg/m<sup>2</sup> IV every 3 weeks. KEYTRUDA<sup>&reg;</sup> was
                                                administered prior to chemotherapy (n=410).<sup>1</sup>
                                            </p>
                                        </div>
                                        <!--end top block-->

                                        <div class="top-block mt-4">
                                            <h4 class="secondary-page-header">PLACEBO</h4>
                                            <p class="white-block common-text-block bg-white text-second mt-3">
                                                Placebo + pemetrexed 500 mg/m<sup>2</sup> + investigator’s choice of
                                                cisplatin 75 mg/m<sup>2</sup> or carboplatin AUC 5 mg/mL/min IV every 3
                                                weeks for 4 cycles followed by placebo + pemetrexed 500 mg/m<sup>2</sup>
                                                IV every 3 weeks (n=206).<sup>1</sup>
                                            </p>
                                        </div>
                                        <!--end top block-->
                                    </div>
                                    <!--end right step section-->
                                </div>
                                <!--end step2-->
                            </div>
                            <!--end step2 content-->

                            <div>
                                <div class="step-3 p-3 d-flex flex-column justify-content-center">
                                    <div class="steps mb-3">
                                        <span>3</span>
                                        <h5>Endpoints</h5>
                                    </div>
                                    <!--end steps-->

                                    <div class="top-step-section">
                                        <h4 class="text-white">Primary Endpoint<sup>1</sup></h4>
                                        <ul class="mb-0">
                                            <li>Overall survival</li>
                                            <li>Progression-free survival <br>(assessed by blinded independent central
                                                review [BICR] using Response Evaluation Criteria in Solid Tumors
                                                [RECIST] 1.1)</li>
                                        </ul>
                                    </div>
                                    <!--end top section-->

                                    <div class="bottom-step-section ">
                                        <h4 class="text-white">Secondary Endpoints <span>(assessed by BICR using RECIST
                                                1.1)<sup>1</sup></span></h4>
                                        <ul>
                                            <li>Objective response rate</li>
                                            <li>Duration of response</li>
                                        </ul>
                                    </div>
                                    <!--end top section-->

                                </div>
                                <!--end step3-->
                            </div>
                            <!--end step3 content-->

                        </div>
                        <!--end slider for mobile devices-->
                    </div>
                    <!--end col 12-->
                </div>
                <!--end mobile stepper tabbed-->
                <!--mobile-->

                <div class="row mt-5 mb-4 desktop-only-flex" id="stepper-display">
                    <div class="col-12">
                        <div class="steps-header d-flex">

                            <div class="steps">
                                <span>1</span>
                                <h5>Patient Population</h5>
                            </div>
                            <!--end steps-->

                            <div class="steps">
                                <span class="line"></span>
                                <span class="study_arm_step">2</span>
                                <h5>Study Arms</h5>
                            </div>
                            <!--end steps-->

                            <div class="steps">
                                <span>3</span>
                                <h5>Endpoints</h5>
                            </div>
                            <!--end steps-->

                        </div>
                        <!--end steps-->
                    </div>
                    <!--end steps-->

                    <div class="col-12">
                        <div class="stepper-ui d-sm-flex">

                            <div class="step-1 justify-content-center d-flex flex-column px-4 px-lg-4">
                                <p><strong>Advanced or metastatic RCC with clear cell component Treatment-naïve</strong></p>
                                <p>IMDC risk categories at baseline:</p>
                                <ul class="list-unstyled step-lister">
                                    <li>31% favourable</li>
                                    <li>56% intermediate</li>
                                    <li>13% poor</li>
                                </ul>
                                <!--end step1 listing-->
                            </div>
                            <!--end step1-->

                            <div class="step-2 d-flex align-items-center px-lg-5 px-md-3 py-4 py-lg-3">
                                <div class="left-step-section">
                                    <img src="img/circle-arrow.png" alt="chart" class="img-fluid">
                                </div>
                                <!--end left step section-->

                                <div class="right-step-section pl-lg-0 pl-md-4 pl-md-0">
                                    <div class="top-block">
                                        <h4 class="secondary-page-header">KEYTRUDA<sup>&reg;</sup> + axitinib</h4>
                                        <p class="primary-block common-text-block back-primary text-white">
                                            200 mg IV every 3 weeks + axitinib 5 mg orally, twice daily
                                        </p>
                                    </div>
                                    <!--end top block-->

                                    <div class="top-block mt-1">
                                        <h4 class="secondary-page-header gray-text">Sunitinib</h4>
                                        <p class="white-block common-text-block bg-secondary-gray">
                                            50 mg orally, once daily for 4 weeks and then off treatment for 2 weeks
                                        </p>
                                    </div>
                                    <!--end top block-->
                                </div>
                                <!--end right step section-->
                            </div>
                            <!--end step2-->

                            <div class="step-3 px-3 d-flex flex-column justify-content-center px-lg-4">

                                <div class="top-step-section">
                                    <h4 class="gray-text-modifi">Primary</h4>
                                    <ul class="mb-0">
                                        <li>Overall survival*</li>
                                        <li>Progression-Free Survival</li>
                                    </ul>
                                </div>
                                <!--end top section-->

                                <div class="bottom-step-section ">
                                    <h4 class="gray-text-modifi">Secondary <span>(assessed by BICR using RECIST 1.1)</span></h4>
                                    <ul>
                                        <li>Overall Response Rate</li>
                                        <li>Duration of response</li>
                                    </ul>
                                </div>
                                <!--end top section-->

                            </div>
                            <!--end step3-->
                        </div>
                        <!--end stepper ui-->
                    </div>
                    <!--end col12-->
                </div>
                <!--end row-->

                <div class="row">
                    <div class="col-12">
                        <div class="bar-footer-content mt-0">
                            <p class="small gray-lighter-text mb-0">Adapted from the Product Monograph.<sup>1</sup></p>
                            <p class="small gray-lighter-text">* OS and PFS were assessed by BICR according to RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</p>
                        </div>
                    </div>
                </div>



                <div class="row mt-4 main_service_div">
                    <div class="col-sm-12 col-md-6 col-lg-5 study_service_content">
                        <div>
                            <p>As in KEYNOTE-426, when axitinib is used in combination with KEYTRUDA<sup>®</sup>, dose escalation to 7 mg twice daily may be considered for patients who tolerated the initial 5 mg twice daily axitinib dose with no >Grade 2 treatment-related adverse events to axitinib and with blood pressure well controlled to ≤150/90 mmHg for 2 consecutive treatment cycles (i.e. 6 weeks). Refer to the axitinib product monograph for recommended axitinib dose information.<sup>1</sup></p>

                            <p>Treatment continued until RECIST 1.1-defined progression of disease as verified by BICR or confirmed by the investigator, unacceptable toxicity, or for KEYTRUDA<sup>®</sup>, for up to 24-months or 35 administrations, whichever was longer. </p>
                        </div>
                    </div>
                    <!--end col sm4-->

                    <div class="col-sm-12 col-md-6 col-lg-5 study_service_content">
                      <div class="study-service-inner">
                           <p>Administration of KEYTRUDA<sup>®</sup> + axitinib was permitted beyond RECIST 1.1-defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. </p>

                       <p>Treatment with pembrolizumab could be reinitiated for subsequent disease progression, and administered for up to 1 additional year.<sup>1</sup></p>

                       <p>Assessment of tumour status was performed at baseline, Week 12, followed by every 6 weeks thereafter until Week 54, then every 12 weeks thereafter.<sup>1</sup></p>
                      </div>
                    </div>
                    <!--end col sm4-->

                </div>
                <!--end row-->
            </div>
            <!--end container-->
            <span id="baseline-link" class="link-grabber"></span>
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-banner-content w-100 baseline-section background-properties line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-green py-5 pos-rel py-100-fixer">

                    <div class="row">

                        <span class="top-redirect-arrow" id="redirectArrow"><img src="img/arrow-content.png"
                                alt="Go Top"></span>


                        <div class="col-lg-7 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header brand-color"><span class="pulsating-circle"></span> Baseline
                                Characteristics <sup>1,4</sup></h2>


                            <div class="chart-img-holder baseline_table mt-4 mb-4 w-100 mobile-chart-crawler">
                                <div class="table-responsive">
                                    <table class="hand-icon-table">
                                        <tr class="table_head_row">
                                            <th class="table_heading">Characteristic</th>
                                            <th class="table_heading">KEYTRUDA<sup>&reg;</sup> + axitinib (n=432)
                                            </th>
                                            <th class="table_heading">Sunitinib (n=429)</th>
                                        </tr>
                                        <tr class="odd">
                                            <td class="strong-col">Men</td>
                                            <td>71.3%</td>
                                            <td>75%</td>
                                        </tr>
                                        <tr class="even">
                                            <td class="strong-col">Women</td>
                                            <td>28.7%</td>
                                            <td>25%</td>
                                        </tr>
                                        <tr class="odd">
                                            <td class="strong-col">Age (median)</td>
                                            <td>62 years</td>
                                            <td>61 years</td>
                                        </tr>
                                        <tr class="even">
                                            <td class="strong-col">Age (range)</td>
                                            <td>30-89 years</td>
                                            <td>26-90 years</td>
                                        </tr>
                                        <tr class="table_chart_head">
                                            <td colspan="1">Geographic region</td>
                                            <td></td>
                                            <td></td>
                                        </tr>
                                        <tr class="even">
                                            <td class="td-pad">North America</td>
                                            <td>24.1%</td>
                                            <td>24.0%</td>
                                        </tr>
                                        <tr class="odd">
                                            <td class="td-pad">Western Europe</td>
                                            <td>24.5%</td>
                                            <td>24.2%</td>
                                        </tr>
                                        <tr class="even">
                                            <td class="td-pad">Rest of the world</td>
                                            <td>
                                                51.4%</td> <td>51.7%
                                            </td>
                                        </tr>
                                        <tr class="table_chart_head">
                                            <td colspan="1">IMDC prognostic risk</td>
                                            <td></td>
                                            <td></td>
                                        </tr>
                                        <tr class="even">
                                            <td class="td-pad">Favourable</td>
                                            <td>31% </td>
                                            <td>30.5%</td>
                                        </tr>
                                        <tr class="odd">
                                            <td class="td-pad">Intermediate</td>
                                            <td>56% </td>
                                            <td>57.3%</td>
                                        </tr>
                                        <tr class="even">
                                            <td class="td-pad">Poor</td>
                                            <td>13%  </td>
                                            <td>12.1%</td>
                                        </tr>
                                        <tr class="table_chart_head">
                                            <td colspan="1">PD-L1 status</td>
                                            <td></td>
                                            <td></td>
                                        </tr>
                                        <tr class="even">
                                            <td class="td-pad">
                                                <1%</td> <td >40.7%
                                            </td>
                                            <td>61.7%</td>
                                        </tr>
                                        <tr class="odd">
                                            <td class="td-pad">≥1%</td>
                                            <td>59.3%</td>
                                            <td>38.3%</td>
                                        </tr>
                                        <tr class="even">
                                            <td class="strong-col">Previous radiotherapy</td>
                                            <td>9.5%</td>
                                            <td>9.3%</td>
                                        </tr>
                                       
                                      
                                        <tr class="odd">
                                            <td class="strong-col">Previous nephrectomy</td>
                                            <td>82.6%</td>
                                            <td>83.4%</td>
                                        </tr>
                                       

                                    </table>
                                </div>
                            </div>
                            <!--end chart img holder-->

                            <div class="download_table download_table_mobile ">
                                <a href="img/Baseline-Characteristics.pdf" class="btn button-second"
                                    download="Baseline-Characteristics.pdf" target="_blank">
                                    <img src="img/download_table.png" alt="download_table"> Download Table</a>

                                <a href="#" class="zoom_icon" data-toggle="modal" data-target="#tableZoom"><img
                                        src="img/zoom_icon.png" alt="zoom"></a>

                                <!-- Modal -->
                                <div class="modal fade custom-zoom-modal" id="tableZoom" tabindex="-1" role="dialog"
                                    aria-labelledby="exampleModalLabel" aria-hidden="true">
                                    <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                        <div class="modal-content">

                                            <div class="modal-body">
                                                <button type="button" class="close" data-dismiss="modal"
                                                    aria-label="Close">
                                                    <span aria-hidden="true">&times;</span>
                                                </button>
                                                <img src="img/Baseline-Characteristics-min.png" alt="table"
                                                    class="img-fluid">
                                            </div>


                                        </div>
                                    </div>
                                </div>


                            </div>
                            <!--end flexbox-->
                        </div>
                        <!--end col md-->
                    </div>
                    <!--end row-->
                </div>
                <!--end container-->
                <span class="link-grabber" id="overall-link"></span>
            </div>
            <!--end section content holder-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 overall-servival line-common-section">
            <div class="container py-5 draw-green py-100-fixer">
                <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Overall Survival <span
                                class="primary_endpoint">(primary endpoint)</span></h2>
                        <p class="common-text">KEYTRUDA<sup>&reg;</sup> + plat/pem demonstrated superior overall
                            survival (OS) compared with placebo + plat/pem (P<0.00001)<sup>1</sup></p>

                    </div>
                    <!--end col-->
                </div>
                <!--end row-->

                <div class="risk_of_death_present overall_all_present">
                    <div class="present_box new-text-fixer">
                        <h3><img src="img/down-arrow.png" alt="down-arrow">51%
                            <span>
                                <h6>reduction in the risk of death<sup>1</sup></h6>
                                <h6>HR<sup>*</sup>=0.49 [95% CI: 0.38-0.64], p<sup>†</sup>&lt;0.00001</h6>
                                <h6>Patient deaths: <br/>31% (KEYTRUDA<sup>&reg;</sup>) vs. 52% (placebo)</h6>
                            </span>
                        </h3>
                    </div>

                </div>


                <div class="row overall_chart_sec">
                    <div class="col-12 col-md-12 pr-sm-2 col-lg-6">
                        <!--highchart generator-->
                        <!-- <div id="container" style="height: auto; min-width: 80%; width:100%;"></div> -->
                        <div class="mobile-chart-crawler">
                            <div class="chart_sec">
                                <div class="chart_left_sec">
                                    <div class="chart_detail">
                                        <div class="chart_color_box">
                                            <span class="color_box"></span>
                                            <p>KEYTRUDA<sup>&reg;</sup> + plat/pem <br> Median OS: not reached</p>
                                        </div>
                                        <div class="chart_color_box">
                                            <span class="color_box plat_pem_color_box"></span>
                                            <p>Placebo+plat/pem<br> Median OS: 11.3 months</p>
                                        </div>
                                    </div>
                                </div>
                                <div class="os_text_sec ostext_mobile">
                                    <p><strong>OS (%)</strong></p>
                                </div>
                                <div class="chart_right_sec hand-icon-chart">
                                    <div class="chart_list">
                                        <ul class="chart_left_list">
                                            <li>100</li>
                                            <li><span>90</span></li>
                                            <li><span>80</span></li>
                                            <li><span>70</span></li>
                                            <li><span>60</span></li>
                                            <li class="line-border"><span>50</span></li>
                                            <li><span>40</span></li>
                                            <li><span>30</span></li>
                                            <li><span>20</span></li>
                                            <li><span>10</span></li>
                                            <li><span>0</span></li>
                                        </ul>
                                    </div>
                                    <div class="chart_list">
                                        <ul class="chart_bottom_list">
                                            <li class="manth_text"><strong>Months</strong></li>
                                            <li>3</li>
                                            <li>6</li>
                                            <li>9</li>
                                            <li>12</li>
                                            <li>15</li>
                                            <li>18</li>
                                            <li>21</li>
                                        </ul>
                                    </div>
                                    <div class="chart_code_text">

                                    </div>
                                    <div class="chart_main_img_sec">
                                        <div class="chart_detail_img">
                                            <img class="chart_green_img" src="img/chart_img1.png" alt="chartimg">
                                            <img class="chart_plat_img" src="img/chart_img2.png" alt="chartimg">
                                        </div>
                                    </div>
                                    <div class="os_text_sec">
                                        <p><strong>OS (%)</strong></p>
                                    </div>
                                    <div class="risk_of_death_present">
                                        <div class="present_box new-text-fixer">
                                            <h3><img src="img/down-arrow.png" alt="down-arrow">51%
                                                <span>
                                                    <h6>reduction in the risk of death<sup>1</sup></h6>
                                                    <h6>HR<sup>*</sup>=0.49 [95% CI: 0.38-0.64],p<sup>†</sup>&lt;0.00001
                                                    </h6>
                                                    <h6>Patient deaths: <br/>31% (KEYTRUDA<sup>&reg;</sup>) vs. 52% (placebo)
                                                    </h6>
                                                </span>
                                            </h3>
                                        </div>

                                    </div>
                                </div>
                            </div>

                            <div class="number_at_rist_sec">
                                <h3 class="number_risk_head">Number at risk </h3>
                                <div class="number_box">
                                    <table>
                                        <tbody>
                                            <tr class="grid-row-data-setter overall-desktop">
                                                <td>KEYTRUDA<sup>&reg;</sup>+plat/pem:</td>
                                                <td>410</td>
                                                <td>377</td>
                                                <td>347</td>
                                                <td>278</td>
                                                <td>163</td>
                                                <td>71</td>
                                                <td>18</td>
                                                <td>0</td>
                                            </tr>
                                            <tr class="grid-row-data-setter overall-desktop">
                                                <td>Placebo+plat/pem:</td>
                                                <td>206</td>
                                                <td>183</td>
                                                <td>149</td>
                                                <td>104</td>
                                                <td>59</td>
                                                <td>25</td>
                                                <td>8</td>
                                                <td>0</td>
                                            </tr>
                                        </tbody>
                                    </table>

                                </div>
                                <p class="merck_cana_text">Adapted from the Product Monograph and Gandhi et
                                    al.<sup>1,2</sup></p>

                            </div>

                            <div class="number_at_rist_sec number_at_rist_sec_mob">
                                <div class="number_box">
                                    <table>
                                        <tbody>
                                            <tr class="number_rist_td">
                                                <td colspan="7">Number at risk</td>
                                            </tr>
                                            <tr class="number_keytruda_td">
                                                <td colspan="7">KEYTRUDA<sup>&reg;</sup>+plat/pem:</td>
                                            </tr>
                                            <tr class="number_at_risk_text grid-row-data-setter overall-mobile">
                                                <td>410</td>
                                                <td>377</td>
                                                <td>347</td>
                                                <td>278</td>
                                                <td>163</td>
                                                <td>71</td>
                                                <td>18</td>
                                                <td>0</td>
                                            </tr>
                                            <tr class="number_plat_td">
                                                <td colspan="7">Placebo+plat/pem:</td>
                                            </tr>
                                            <tr class="number_at_risk_text_row grid-row-data-setter overall-mobile">
                                                <td>206</td>
                                                <td>183</td>
                                                <td>149</td>
                                                <td>104</td>
                                                <td>59</td>
                                                <td>25</td>
                                                <td>8</td>
                                                <td>0</td>
                                            </tr>
                                        </tbody>
                                    </table>

                                </div>
                                <p class="merck_cana_text">Adapted from the Product Monograph and Gandhi et
                                    al.<sup>1,2</sup></p>

                            </div>
                        </div>

                        <div class="chart_download">
                            <a href="img/Overall_Survival.pdf" target="_blank" download class="download-table-button">
                                <img src="img/download_table.png" alt="download_table"> Download Graph
                            </a>
                            <a href="#" data-toggle="modal" data-target="#graphZoom1">
                                <img src="img/zoom_icon.png" alt="zoom">
                            </a>

                            <div class="modal fade custom-zoom-modal" id="graphZoom1" tabindex="-1" role="dialog"
                                aria-labelledby="exampleModalLabel" aria-hidden="true">
                                <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                    <div class="modal-content">

                                        <div class="modal-body rounded-modal">
                                            <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                                                <span aria-hidden="true">×</span>
                                            </button>
                                            <img src="img/Overall-survival-chart-1.png" alt="table" class="img-fluid">
                                        </div>


                                    </div>
                                </div>
                            </div>

                        </div>

                    </div>
                    <!--end col12-->

                    <div class="col-12 col-md-8 offset-md-2 offset-lg-1 col-lg-5 mt-ipad-setting">

                        <!-- <div class="reduction-block px-2 pl-4 mb-4 d-flex align-item-center"> -->
                        <!-- <h2 class="mb-0">51% <i class="fas fa-arrow-down"></i> <span>reduction in the risk of death</span></h2> -->
                        <!-- </div> -->

                        <div class="rate-column wo-heading">

                            <div class="container-fluid progress_sec">
                                <div class="plat_pem_sec">
                                    <h3 class="keytruda_plat_text">KEYTRUDA<sup>&reg;</sup> + plat/pem</h3>
                                    <h3 class="plat_pem_text">Placebo + plat/pem</h3>
                                </div>
                                <div class="row response-chart-holder first_chart_holder">
                                    <div class="left-chart-response col text-center">
                                        <div class="progressbar" data-animate="false">
                                            <div class="circle" data-percent="85">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-second mt-1">OS rate at <b>6 months</b><sup>1</sup></h5>
                                    </div>
                                    <!--end left chart response-->


                                    <div class="right-chart-response col text-center">
                                        <!-- <img src="img/chart-2-graph.png" alt="chart" class="img-fluid"> -->
                                        <!-- <div class="chart2" data-size="130" data-value="49"></div> -->
                                        <div class="progressbar1" data-animate="false">
                                            <div class="circle1" data-percent="72">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-second mt-1">OS rate at <b>6 months</b><sup>1</sup></h5>
                                        <div class="vs_text"><span class="chart_vs">vs</span></div>
                                    </div>
                                    <!--end right chart response-->
                                </div>
                                <!--end flex container-->
                                <div class="row response-chart-holder second_chart_holder">
                                    <div class="left-chart-response col text-center">
                                        <div class="progressbar3" data-animate="false">
                                            <div class="circle3" data-percent="78">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-second mt-1">OS rate at <b>9 months</b><sup>1</sup></h5>
                                    </div>
                                    <!--end left chart response-->


                                    <div class="right-chart-response col text-center">
                                        <!-- <img src="img/chart-2-graph.png" alt="chart" class="img-fluid"> -->
                                        <!-- <div class="chart2" data-size="130" data-value="49"></div> -->
                                        <div class="progressbar4" data-animate="false">
                                            <div class="circle4" data-percent="56">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-second mt-1">OS rate at <b>9 months</b><sup>1</sup></h5>
                                        <div class="vs_text"><span class="chart_vs">vs</span></div>
                                    </div>
                                    <!--end right chart response-->
                                </div>
                                <!--end flex container-->

                            </div>
                            <!--end container fluid-->
                        </div>
                        <!--end rate column-->
                    </div>
                    <!--end col12-->
                </div>
                <!--end row-->
                <span class="link-grabber" id="progression-link"></span>
            </div>
            <!--end container-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 progression-section line-common-section">
            <div class="container py-5 draw-white py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-8 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading text-white progres_text"><span class="pulsating-circle"></span>
                            Progression-Free Survival <span class="primary_endpoint">(primary endpoint)</span></h2>
                        <p class="text-white">KEYTRUDA<sup>&reg;</sup> + plat/pem significantly extended
                            progression-free survival (PFS) compared with placebo + plat/pem (p<0.00001)<sup>1</sup></p>
                    </div>
                    <!--end col-->
                </div>
                <!--end row-->


                <div class="risk_of_death_present risk_of_death_progess_free dis-fix">
                    <div class="present_box new-text-fixer">
                        <h3><img src="img/down-arrow.png" alt="down-arrow">48%
                            <span>
                                <h6>reduction in the risk of progression or death<sup>1</sup></h6>
                                <h6>HR<sup>*</sup>=0.52 (95% CI: 0.43-0.64), p<sup>†</sup>&lt;0.00001</h6>
                                <h6>Patients with disease progression or death:<br />60% (KEYTRUDA<sup>&reg;</sup>) vs.
                                    81% (placebo)</h6>
                            </span>
                        </h3>
                    </div>
                </div>




                <div class="row overall_chart_sec">
                    <div class="col-12 col-lg-6 pr-sm-2">
                        <!-- <div id="container2" style="height: auto; min-width: 80%; width:100%;"></div> -->
                        <div class="mobile-chart-crawler">
                            <div class="chart_sec">
                                <div class="chart_left_sec">
                                    <div class="chart_detail">
                                        <div class="chart_color_box">
                                            <span class="color_box"></span>
                                            <p>KEYTRUDA<sup>&reg;</sup>+plat/pem <br>Median PFS: 8.8 months</p>
                                        </div>
                                        <div class="chart_color_box">
                                            <span class="color_box plat_pem_color_box"></span>
                                            <p>Placebo+plat/pem <br>Median PFS: 4.9 months</p>
                                        </div>
                                    </div>
                                </div>
                                <div class="os_text_sec ostext_mobile">
                                    <p><strong>PFS (%)</strong></p>
                                </div>
                                <div class="chart_right_sec hand-icon-chart icon-white">
                                    <div class="chart_list">
                                        <ul class="chart_left_list">
                                            <li>100</li>
                                            <li><span>90</span></li>
                                            <li><span>80</span></li>
                                            <li><span>70</span></li>
                                            <li><span>60</span></li>
                                            <li class="line-border"><span>50</span></li>
                                            <li><span>40</span></li>
                                            <li><span>30</span></li>
                                            <li><span>20</span></li>
                                            <li><span>10</span></li>
                                            <li><span>0</span></li>
                                        </ul>
                                    </div>
                                    <div class="chart_list">
                                        <ul class="chart_bottom_list">
                                            <li class="manth_text"><strong>Months</strong></li>
                                            <li>3</li>
                                            <li>6</li>
                                            <li>9</li>
                                            <li>12</li>
                                            <li>15</li>
                                            <li>18</li>
                                            <li>21</li>
                                        </ul>
                                    </div>
                                    <div class="chart_code_text">

                                    </div>
                                    <div class="chart_main_img_sec">
                                        <div class="chart_detail_img">
                                            <img class="chart_green_img" src="img/progres_chart_img1.png"
                                                alt="chartimg">
                                            <img class="chart_plat_img" src="img/progres_chart_img2.png" alt="chartimg">
                                        </div>
                                    </div>
                                    <div class="os_text_sec">
                                        <p><strong>PFS (%)</strong></p>
                                    </div>
                                    <div class="risk_of_death_present">
                                        <div class="present_box new-text-fixer">
                                            <h3><img src="img/down-arrow.png" alt="down-arrow">48%
                                                <span>
                                                    <h6>reduction in the risk of progression or death<sup>1</sup></h6>
                                                    <h6>HR<sup>*</sup>=0.52 (95% CI: 0.43-0.64),
                                                        p<sup>†</sup>&lt;0.00001</h6>
                                                    <h6>Patients with disease progression or death: <br />60%
                                                        (KEYTRUDA<sup>&reg;</sup>) vs. 81% (placebo)</h6>
                                                </span>
                                            </h3>
                                        </div>
                                    </div>
                                </div>
                            </div>

                            <div class="number_at_rist_sec">
                                <h3 class="number_risk_head">Number at risk </h3>
                                <div class="number_box">
                                    <table>
                                        <tbody>
                                            <tr class="grid-row-data-setter overall-desktop progression-desktop">
                                                <td>KEYTRUDA<sup>&reg;</sup>+plat/pem:</td>
                                                <td>410</td>
                                                <td>322</td>
                                                <td>256</td>
                                                <td>149</td>
                                                <td>60</td>
                                                <td>17</td>
                                                <td>5</td>
                                                <td>0</td>
                                            </tr>
                                            <tr class="grid-row-data-setter overall-desktop progression-desktop">
                                                <td>Placebo+plat/pem:</td>
                                                <td>206</td>
                                                <td>141</td>
                                                <td>80</td>
                                                <td>40</td>
                                                <td>16</td>
                                                <td>3</td>
                                                <td>1</td>
                                                <td>0</td>
                                            </tr>
                                        </tbody>
                                    </table>



                                </div>
                                <p class="merck_cana_text text-white">Adapted from the Product Monograph and Gandhi et
                                    al.<sup>1,2</sup></p>
                            </div>
                            <div class="number_at_rist_sec number_at_rist_sec_mob">
                                <div class="number_box">
                                    <table>
                                        <tbody>
                                            <tr class="number_rist_td">
                                                <td colspan="7">Number at risk</td>
                                            </tr>
                                            <tr class="number_keytruda_td">
                                                <td colspan="7">KEYTRUDA<sup>&reg;</sup>+plat/pem:</td>
                                            </tr>
                                            <tr
                                                class="number_at_risk_text grid-row-data-setter overall-mobile progression-mobile">
                                                <td>410</td>
                                                <td>322</td>
                                                <td>256</td>
                                                <td>149</td>
                                                <td>60</td>
                                                <td>17</td>
                                                <td>5</td>
                                                <td>0</td>
                                            </tr>
                                            <tr class="number_plat_td">
                                                <td colspan="7">Placebo+plat/pem:</td>
                                            </tr>
                                            <tr
                                                class="number_at_risk_text_row grid-row-data-setter overall-mobile progression-mobile">
                                                <td>206</td>
                                                <td>141</td>
                                                <td>80</td>
                                                <td>40</td>
                                                <td>16</td>
                                                <td>3</td>
                                                <td>1</td>
                                                <td>0</td>
                                            </tr>
                                        </tbody>
                                    </table>

                                </div>
                                <p class="merck_cana_text text-white">Adapted from the Product Monograph and Gandhi et
                                    al.<sup>1,2</sup></p>

                            </div>
                        </div>

                        <div class="chart_download">
                            <a href="img/Progression-Free-Survival.pdf" target="_blank" download
                                class="download-table-button">
                                <img src="img/download_table.png" alt="download_table"> Download Graph
                            </a>
                            <a href="#" data-toggle="modal" data-target="#graphZoom2">
                                <img src="img/zoom_icon.png" alt="zoom">
                            </a>

                            <div class="modal fade custom-zoom-modal" id="graphZoom2" tabindex="-1" role="dialog"
                                aria-labelledby="exampleModalLabel" aria-hidden="true">
                                <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                    <div class="modal-content">

                                        <div class="modal-body rounded-modal">
                                            <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                                                <span aria-hidden="true">×</span>
                                            </button>
                                            <img src="img/Progression-Free-Survival-chart-1.png" alt="table"
                                                class="img-fluid">
                                        </div>


                                    </div>
                                </div>
                            </div>

                        </div>
                    </div>
                    <!--end col12-->

                    <div class="col-12 col-lg-5 col-md-8 offset-md-2 offset-lg-1 mt-ipad-setting">

                        <!-- <div class="reduction-block px-2 pl-4 mb-4 d-flex align-item-center"> -->
                        <!-- <h2 class="mb-0">48% <i class="fas fa-arrow-down"></i> <span>reduction in the risk of death</span></h2> -->
                        <!-- </div> -->

                        <div class="rate-column rate-dark wo-heading">
                            <div class="container-fluid viewport-chart3">
                                <div class="plat_pem_sec">
                                    <h3 class="keytruda_plat_text">KEYTRUDA<sup>&reg;</sup> + plat/pem</h3>
                                    <h3 class="plat_pem_text">Placebo + plat/pem</h3>
                                </div>
                                <div class="row response-chart-holder first_chart_holder">
                                    <div class="left-chart-response col text-center">
                                        <div class="progressbar5" data-animate="false">
                                            <div class="circle5" data-percent="66">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-white text-second mt-1">PFS rate at 6 months<sup>1</sup></h5>
                                    </div>
                                    <!--end left chart response-->


                                    <div class="right-chart-response col text-center">
                                        <!-- <img src="img/chart-2-dark.png" alt="chart" class="img-fluid"> -->
                                        <div class="progressbar6" data-animate="false">
                                            <div class="circle6" data-percent="40">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-white text-second mt-1">PFS rate at 6 months<sup>1</sup></h5>
                                        <div class="vs_text"><span class="chart_vs">vs</span></div>
                                    </div>
                                    <!--end right chart response-->
                                </div>
                                <!--end flex container-->
                                <div class="row response-chart-holder">
                                    <div class="left-chart-response col text-center">
                                        <div class="progressbar7" data-animate="false">
                                            <div class="circle7" data-percent="48">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-white text-second mt-1">PFS rate at 9 months<sup>1</sup></h5>
                                    </div>
                                    <!--end left chart response-->


                                    <div class="right-chart-response col text-center">
                                        <!-- <img src="img/chart-2-dark.png" alt="chart" class="img-fluid"> -->
                                        <div class="progressbar8" data-animate="false">
                                            <div class="circle8" data-percent="25">
                                                <div></div>
                                            </div>
                                        </div>
                                        <h5 class="text-white text-second mt-1">PFS rate at 9 months<sup>1</sup></h5>
                                        <div class="vs_text"><span class="chart_vs">vs</span></div>
                                    </div>
                                    <!--end right chart response-->
                                </div>
                                <!--end flex container-->
                            </div>
                            <!--end container fluid-->
                        </div>
                        <!--end rate column-->
                    </div>
                    <!--end col12-->
                </div>
                <!--end row-->
            </div>
            <!--end container-->
            <span class="link-grabber" id="objective-response-link"></span>
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 objective-response line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Objective Response Rate
                            <span class="primary_endpoint">(secondary endpoint)</span></h2>
                        <p class="common-text">KEYTRUDA<sup>&reg;</sup> + plat/pem significantly increased objective
                            response rate (ORR) compared with placebo + plat/pem<sup>1</sup></p>
                    </div>
                    <!--end col-->
                </div>
                <!--end row-->

                <div class="row mt-sm-5 mt-2 mt-md-5 mt-lg-5">
                    <div class="col-12 col-lg-5 col-md-10">

                        <div class="rate-column mr-sm-5 mr-md-0">
                            <h6 class="orr_text">ORR<sup>‡</sup>:</h6>

                            <div class="container-fluid">
                                <div class="row response-chart-holder custom-progressbar">
                                    <div class="left-chart-response col text-center">
                                        <!-- <img src="img/chart-response.png" alt="chart" class="img-fluid"> -->
                                        <div class="progressbar9" data-animate="false">
                                            <div class="circle9" data-percent="48">
                                                <div></div>
                                                <img src="img/chart-user-group1.png" alt="">
                                            </div>
                                        </div>
                                        <h5 class="text-second mt-3"> (95% CI: 43-53) <br>KEYTRUDA<sup>&reg;</sup> +
                                            plat/pem</h5>
                                    </div>
                                    <!--end left chart response-->

                                    <div class="right-chart-response col text-center">
                                        <!-- <img src="img/chart-response2.png" alt="chart" class="img-fluid"> -->
                                        <div class="progressbar10" data-animate="false">
                                            <div class="circle10" data-percent="19">
                                                <div></div>
                                                <img src="img/chart-user-group2.png" alt="">
                                                </div> 
                                                </div>
                                         <h5 class="text-second mt-3">(95% CI: 14-25) <br> placebo + plat/pem </h5>
										 <div class="vs_text"><span class="chart_vs">vs</span> <span class="object_text">P<sup>§</sup><0.0001 </span></div>
                                    </div><!--end right chart response-->
									
                                </div><!--end flex container-->
								
								
								
                            </div><!--end container fluid-->  
														
                       </div><!--end rate column-->
						<div class="complete_respon_text px-0">
							<p>Complete response was 0.5% in both arms; partial response was 47% in the KEYTRUDA<sup>&reg;</sup> + plat/pem arm compared with 18% in the placebo + plat/pem arm (p<sup>§</sup><0.0001)<sup>1</sup></p>
						</div>	

                    </div><!--end col 6-->


                    <div class="col-12 col-lg-6 offset-lg-1 offset-md-0 mt-ipad-setting col-md-10">
						<h3 class="res_duration_text">Response duration<sup>1</sup></h3>
						<div class="response_table_sec">
                       <table class="table table-striped table-responsive-sm custom-table hand-icon-table">

                        <thead class="thead-dark">
                          <tr>
							<th></th>
                            <th>KEYTRUDA<sup>&reg;</sup> + plat/pem</th>
							<th>Placebo + plat/pem</th>
                          </tr>
                        </thead>

                        <tbody>
                          <tr class="first-row">
                            <td>Median</td>
                            <td>11.2 months</td>
                            <td>7.8 months</td>
                          </tr>

                           <tr>
                            <td>% with duration ≥6 months<sup>¶</sup></td>
                            <td>81%</td>
                            <td>63%</td>
                          </tr>

                           <tr>
                            <td>% with duration ≥9 months<sup>¶</sup></td>
                            <td>60%</td>
                            <td>44%</td>
                          </tr>

                        </tbody><!--end tbody-->
                      </table><!--end table-->
					  </div>
                      <div class="download-buttons-holder">
                       
                        <a href="img/response-duration.pdf" target="_blank" download="" class="download-button">
                            <img src="img/download_table.png" alt="download_table"> Download Table
                        </a>
                        <a href="#" data-toggle="modal" data-target="#table1">
                            <img src="img/zoom_icon.png" alt="zoom">
                        </a>
                        <div class="modal fade custom-zoom-modal" id="table1" tabindex="-1" role="dialog"
                             aria-labelledby="exampleModalLabel" aria-hidden="true">
                            <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                <div class="modal-content">
                                    <div class="modal-body rounded-modal">
                                        <button type="button" class="close" data-dismiss="modal"
                                            aria-label="Close">
                                            <span aria-hidden="true">×</span>
                                         </button>
                                        <img src="img/response-duration-table.png" alt="table"
                                                    class="img-fluid">
                                    </div>


                                </div>
                            </div>
                        </div>


                      </div>
                                <div class="response_detail_list">
                                <ul>
                                    <li>* Based on the stratified Cox proportional hazard model</li>
                                    <li>† Based on stratified log-rank test</li>
                                    <li>‡ Based on patients with a best overall response as confirmed complete or
                                        partial response</li>
                                    <li>§ Based on Miettinen and Nurminen method stratified by PD-L1 status, platinum
                                        chemotherapy and smoking status</li>
                                    <li>¶ Based on Kaplan-Meier estimation</li>
                                </ul>
                            </div>
                                <!--end container fluid-->

                            </div>
                            <!--end rate column-->
                           <!--  <div class="complete_respon_text">
                                <p>Complete response was 0.5% in both arms; partial response was 47% in the
                                    KEYTRUDA<sup>&reg;</sup> + plat/pem arm compared with 18% in the placebo + plat/pem
                                    arm (p<sup>§</sup>
                                    <0.0001)<sup>1</sup>
                                </p>
                            </div>

                        </div> -->
                        <!--end col 6-->


                        <div class="col-12 col-lg-6 offset-lg-1 offset-md-0 mt-ipad-setting col-md-10 d-none">
                            <h3 class="res_duration_text">Response duration<sup>1</sup></h3>
                            <div class="response_table_sec">
                                <table class="table table-striped table-responsive-sm custom-table hand-icon-table">

                                    <thead class="thead-dark">
                                        <tr>
                                            <th></th>
                                            <th>KEYTRUDA<sup>&reg;</sup> + plat/pem</th>
                                            <th>Placebo + plat/pem</th>
                                        </tr>
                                    </thead>

                                    <tbody>
                                        <tr class="first-row">
                                            <td>Median</td>
                                            <td>11.2 months</td>
                                            <td>7.8 months</td>
                                        </tr>

                                        <tr>
                                            <td>% with duration ≥6 months<sup>¶</sup></td>
                                            <td>81%</td>
                                            <td>63%</td>
                                        </tr>

                                        <tr>
                                            <td>% with duration ≥9 months<sup>¶</sup></td>
                                            <td>60%</td>
                                            <td>44%</td>
                                        </tr>

                                    </tbody>
                                    <!--end tbody-->
                                </table>
                                <!--end table-->
                            </div>
                            <div class="download-buttons-holder">

                                <a href="img/response-duration.pdf" target="_blank" download="" class="download-button">
                                    <img src="img/download_table.png" alt="download_table"> Download Table
                                </a>
                                <a href="#" data-toggle="modal" data-target="#table1">
                                    <img src="img/zoom_icon.png" alt="zoom">
                                </a>

                                <div class="modal fade custom-zoom-modal" id="table1" tabindex="-1" role="dialog"
                                    aria-labelledby="exampleModalLabel" aria-hidden="true">
                                    <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                        <div class="modal-content">

                                            <div class="modal-body rounded-modal">
                                                <button type="button" class="close" data-dismiss="modal"
                                                    aria-label="Close">
                                                    <span aria-hidden="true">×</span>
                                                </button>
                                                <img src="img/response-duration-table.png" alt="table"
                                                    class="img-fluid">
                                            </div>


                                        </div>
                                    </div>
                                </div>
                            </div>
                            <!--end downlads button holder-->

                            <div class="response_detail_list">
                                <ul>
                                    <li>* Based on the stratified Cox proportional hazard model</li>
                                    <li>† Based on stratified log-rank test</li>
                                    <li>‡ Based on patients with a best overall response as confirmed complete or
                                        partial response</li>
                                    <li>§ Based on Miettinen and Nurminen method stratified by PD-L1 status, platinum
                                        chemotherapy and smoking status</li>
                                    <li>¶ Based on Kaplan-Meier estimation</li>
                                </ul>
                            </div>

                        </div>
                        <!--end col 6-->
                    </div>
                    <!--end row-->
                </div>
                <!--end container-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->

        <!--section ends here-->

        <!--section starts here-->
        <section id="section-3"
            class="page-banner-content safety w-100 background-properties back-effect line-common-section">
            <div class="section-content-holder w-100">
                <div class="container draw-white main_safity_contain py-100-fixer">
                    <div class="row main_safity">
                        <div class="col-lg-7 col-md-12 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle"></span> Safety Profile</h2>
                            <p class="page-lead">In this section the safety data from the pivotal study KEYNOTE-189
                                is presented. Treatment discontinuations and adverse events leading to treatment
                                discontinuation are also described.</p>
                        </div>
                        <!--end col md-->

                        <div
                            class="col-lg-4 col-md-6 offset-lg-1 offset-md-0 content-right mt-md-3 mt-lg-0 mt-sm-0 mt-0">

                            <ul class="banner-section-listing">
                                <li><a href="#adverse-link">Adverse Events</a></li>
                                <li><a href="#discontinuations-link">Discontinuations</a></li>
                            </ul>
                            <!--end banner section listing-->
                        </div>
                        <!--end banner accordion section-->
                    </div>
                    <!--end row-->
                </div>
                <!--end container-->
                <span class="link-grabber" id="adverse-link"></span>
            </div>
            <!--end section content holder-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 adverse-event line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <div class="row">
                    <div class="col-12 col-md-12 col-lg-9 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Adverse Events</h2>
                        <p class="common-text">KEYTRUDA<sup>&reg;</sup> + plat/pem was generally well tolerated in
                            patients with non-squamous mNSCLC</p>
                    </div>
                    <!--end col-->
                </div>
                <!--end row-->

                <div class="row mt-4">
                    <div class="col-12">
                        <h4 class="secondary-page-header">Most common treatment-related adverse events (AEs) with
                            KEYTRUDA<sup>&reg;</sup> regimen (≥20% of patients)<sup>1</sup></h4>
                        <div class=" response_table_sec">
                            <table
                                class="table table-striped table-responsive-sm custom-table mt-4 mb-1 hand-icon-table nausea-table">

                                <thead class="thead-dark">
                                    <tr>
                                        <th colspan="1"></th>
                                        <th colspan="3">KEYTRUDA<sup>&reg;</sup> + plat/pem n=405</th>
                                        <th colspan="3">Placebo + plat/pem n=202</th>
                                    </tr>
                                </thead>

                                <tbody>
                                    <tr class="first-row">
                                        <td>Adverse Reaction</td>
                                        <td>Any Grade</td>
                                        <td>Grade 3</td>
                                        <td>Grade 4</td>
                                        <td>Any Grade</td>
                                        <td>Grade 3</td>
                                        <td>Grade 4</td>
                                    </tr>

                                    <tr>
                                        <td>Nausea</td>
                                        <td>46.2%</td>
                                        <td>3%</td>
                                        <td>-</td>
                                        <td>44.6%</td>
                                        <td>2%</td>
                                        <td>-</td>
                                    </tr>

                                    <tr>
                                        <td>Anemia</td>
                                        <td>38.0%</td>
                                        <td>13.1%</td>
                                        <td>0.5%</td>
                                        <td>38.1%</td>
                                        <td>13.4%</td>
                                        <td>-</td>
                                    </tr>

                                    <tr>
                                        <td>Fatigue</td>
                                        <td>33.1%</td>
                                        <td>4.9%</td>
                                        <td>-</td>
                                        <td>30.7%</td>
                                        <td>1.5%</td>
                                        <td>-</td>
                                    </tr>

                                    <tr>
                                        <td>Neutropenia</td>
                                        <td>24.9%</td>
                                        <td>8.4%</td>
                                        <td>6.2%</td>
                                        <td>22.3%</td>
                                        <td>7.9%</td>
                                        <td>3.0%</td>
                                    </tr>

                                    <tr>
                                        <td>Decreased appetite</td>
                                        <td>20.7%</td>
                                        <td>1.0%</td>
                                        <td>-</td>
                                        <td>20.8%</td>
                                        <td>0.5%</td>
                                        <td>-</td>
                                    </tr>
                                </tbody>
                                <!--end tbody-->
                            </table>
                            <!--end table-->


                        </div>

                    </div>


                    <div class="col-12">
                        <div class="adver_event">
                            <p>The most common Grade 3-5 treatment-related AEs for patients treated with
                                KEYTRUDA<sup>&reg;</sup> were neutropenia (14.6%), anemia (13.6%), thrombocytopenia
                                (7.7%) and febrile neutropenia (5.9%).<sup>1</sup></p>
                        </div>

                        <div class="download-buttons-holder">

                            <a href="img/Adverse-events.pdf" target="_blank" download="" class="download-button">
                                <img src="img/download_table.png" alt="download_table"> Download Table
                            </a>
                            <a href="#" data-toggle="modal" data-target="#table2">
                                <img src="img/zoom_icon.png" alt="zoom">
                            </a>

                            <div class="modal fade custom-zoom-modal" id="table2" tabindex="-1" role="dialog"
                                aria-labelledby="exampleModalLabel" aria-hidden="true">
                                <div class="modal-dialog modal-lg modal-dialog-centered" role="document">
                                    <div class="modal-content">

                                        <div class="modal-body rounded-modal">
                                            <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                                                <span aria-hidden="true">×</span>
                                            </button>
                                            <img src="img/Adverse-events-table.png" alt="table" class="img-fluid">
                                        </div>


                                    </div>
                                </div>
                            </div>
                        </div>

                        <span class="link-grabber" id="discontinuations-link"></span>
                    </div>
                    <!--end col12-->
                </div>
                <!--end row-->

                <div class="row discontinu_sec">
                    <div class="col-12 col-md-7 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Discontinuations</h2>

                    </div>
                    <!--end col-->
                </div>
                <!--end row-->

                <div class="row mt-lg-5 mt-md-5 mt-3 mt-sm-5">
                    <div class="col-sm-6 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/desconti_icon1.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div>
                        <!--end icon holder-->

                        <div class="service-block-content px-md-1 px-lg-4">
                            <p class="text-second">Treatment was discontinued for treatment-related AEs in: 9.6% of the
                                405 patients receiving KEYTRUDA<sup>&reg;</sup> + plat/pem and in 4.0% of the 202
                                patients receiving placebo + plat/pem.<sup>1</sup></p>
                        </div>
                        <!--end service block content-->
                    </div>
                    <!--end col sm4-->

                    <div class="col-sm-6 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/desconti_icon2.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div>
                        <!--end icon holder-->

                        <div class="service-block-content px-md-1 px-lg-4">
                            <p class="text-second">The most common treatment-related AEs leading to study drug
                                discontinuation (occurring in > 3 patients) were acute kidney injury (n=7) and
                                pneumonitis (n=7).<sup>1</sup></p>
                        </div>
                        <!--end service block content-->
                    </div>
                    <!--end col sm4-->

                    <div class="col-sm-6 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/desconti_icon3.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div>
                        <!--end icon holder-->

                        <div class="service-block-content px-md-1 px-lg-4">
                            <p class="text-second">The median time to discontinuation for treatment-related AEs was
                                <span>4.0 months.<sup>1</sup></span></p>
                        </div>
                        <!--end service block content-->
                    </div>
                    <!--end col sm4-->

                </div>
                <!--end row-->
            </div>
            <!--end container-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section id="section-4"
            class="page-banner-content dosing w-100 background-properties back-effect line-common-section">

            <div class="section-content-holder w-100">
                <div class="container draw-white py-5 py-100-fixer">
                    <div class="row">
                        <div class="col-md-12 col-lg-7 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle"></span> Dosing</h2>
                            <p class="page-lead">This section presents KEYTRUDA<sup>&reg;</sup>'s recommended dose and
                                administration as well as guidance for use with chemotherapy.</p>
                        </div>
                        <!--end col md-->
                    </div>
                    <!--end row-->
                </div>
                <!--end container-->
            </div>
            <!--end section content holder-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 recommended-dose line-common-section">
            <div class="container draw-green recom_contain py-100-fixer">

                <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        <h2 class="common-page-heading"><span class="pulsating-circle"></span> Recommended Dose</h2>
                    </div>
                    <!--end col-->
                </div>
                <!--end row-->

                <div class="row mt-5 second-row">
                    <div class="col-sm-6 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/keyicon-5.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div>
                        <!--end icon holder-->

                        <div class="service-block-content px-md-4 ">
                            <p class="text-second">200 mg fixed dose by IV infusion</p>
                        </div>
                        <!--end service block content-->
                    </div>
                    <!--end col sm4-->

                    <div class="col-sm-6 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/keyicon-6.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div>
                        <!--end icon holder-->

                        <div class="service-block-content px-md-4 ">
                            <p class="text-second">Over 30 minutes</p>
                        </div>
                        <!--end service block content-->
                    </div>
                    <!--end col sm4-->

                    <div class="col-sm-6 col-md-4 service-block text-center">
                        <div class="icon-holder">
                            <img src="img/keyicon-7.png" alt="keyicon" class="img-fluid">
                            <span class="line"></span>
                        </div>
                        <!--end icon holder-->

                        <div class="service-block-content px-md-4 ">
                            <p class="text-second">Every 3 weeks</p>
                        </div>
                        <!--end service block content-->
                    </div>
                    <!--end col sm4-->
                </div>
                <!--end row-->
                <div class="recommed_para recommed_desktop">
                    <p>Treatment until disease progression, unacceptable toxicity or up to 24 months in patients without
                        disease progression.<sup>1</sup></p>
                    <p><b>When administering KEYTRUDA<sup>&reg;</sup> as part of a combination with pemetrexed and
                            platinum chemotherapy, KEYTRUDA<sup>&reg;</sup> should be administered
                            first.</b><sup>1</sup></p>
                    <p>See also the Product Monographs for pemetrexed and the selected platinum
                        chemotherapy.<sup>1</sup></p>
                    <p class="product_mono_para">For more information about dosing and dose modifications, please see
                        the <a href="https://www.merck.ca/confirm-monograph.xhtml?file=KEYTRUDA-PM_E.pdf" target="_blank">Product
                            Monograph.</a></p>
                </div>
            </div>
            <!--end container-->
            <div class="container draw-green recommed_mobile">
                <div class="recommed_para">
                    <p>Treatment until disease progression, unacceptable toxicity or up to 24 months in patients without
                        disease progression.<sup>1</sup></p>
                    <p><b>When administering KEYTRUDA<sup>&reg;</sup> as part of a combination with pemetrexed and
                            platinum chemotherapy, KEYTRUDA<sup>&reg;</sup> should be administered
                            first.</b><sup>1</sup></p>
                    <p>See also the Product Monographs for pemetrexed and the selected platinum
                        chemotherapy.<sup>1</sup></p>
                    <p class="product_mono_para">For more information about dosing and dose modifications, please see
                        the <a href="https://www.merck.ca/confirm-monograph.xhtml?file=KEYTRUDA-PM_E.pdf">Product Monograph.</a></p>
                </div>
            </div>
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section
            class="page-banner-content merck-care w-100 background-properties back-effect light line-common-section"
            id="section-5">

            <div class="section-content-holder w-100">
                <div class="container draw-white oncology_program_sec py-100-fixer">
                    <div class="row">
                        <div class="col-md-12 col-lg-9 text-white content-left content_left_mobile">
                            <h2 class="section-header"><span class="pulsating-circle"></span>MERCK Care<sup>™</sup>
                                Oncology Program </h2>
                            <p class="page-lead">The Merck Care<sup>TM</sup> Oncology Program offers free, confidential
                                patient-assistance services for patients who have been prescribed
                                KEYTRUDA<sup>&reg;</sup>. Please see enrollment form for more details on inclusion
                                criteria.</p>
                        </div>
                        <!--end col md-->

                    </div>
                    <!--end row-->

                </div>
                <!--end container-->
            </div>
            <!--end section content holder-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 oncology-section line-common-section">
            <div class="container py-5 draw-green py-100-fixer">

                <!--  <div class="row">
                    <div class="col-12 col-lg-7 col-md-12 content_left_mobile">
                        
                    </div>
                </div>-->

                <div class="row program_services_sec">
                    <div class="col-md-12 col-sm-12 col-12 pr-lg-5 pr-md-0 col-lg-6">
                        <h2 class="common-page-heading"><span class="pulsating-circle" id="line-ends"></span>Program
                            Services</h2>
                        <h4 class="secondary-page-header mt-md-5 cus_ml">Services may include, depending on eligibility:</h4>
                        <ul class="custom-listing cus-ul-ml">
                            <li>Reimbursement</li>
                            <li>Compassionate assistance</li>
                            <li>Financial assistance</li>
                            <li>Nursing support services</li>
                        </ul>
                        <!--end custom listing-->
                        <p class="text-second cus-p-ml">These services will be presented to the patient during an initial call
                            with the Program nurse.</p>
                        <p class="text-second cus-p-ml">Merck Care™ Oncology Program is limited to the conditions disclosed in
                            the enrollment form.</p>
                    </div>
                    <!--end col6-->

                    <div class="col-md-12 col-12 col-lg-6 mt-4">
                        <ul class="list-group custom-list-group">
                            <li class="list-group-item"><span class="list_img"><img src="img/watch_icon.png"
                                        alt="mobile" class="img-fluid watch_icon_desktop"><img src="img/Clock_Icon.png"
                                        alt="mobile" class="img-fluid watch_icon_mobile"></span> <span
                                    class="program_ser_content"><span>Hours of Operation:</span> <br><span
                                        class="contact_detail">Monday to Friday from 8 a.m. - 8 p.m. EST</span></span>
                            </li>
                            <li class="list-group-item"><span class="list_img"><img src="img/mob-icon.png" alt="mobile"
                                        class="img-fluid"></span> <span class="program_ser_content"><span>Contact
                                        us:</span> <span class="contact_detail hover contact_text_brdr"><a
                                            href="tel:18555499416">1-855-549-9416</a></span></span></li>

                            <li class="list-group-item"><span class="list_img"><img src="img/email-icon.png" alt="email"
                                        class="img-fluid"></span><span class="program_ser_content"> <span>Email
                                        us:</span> <span class="contact_detail hover contact_text_brdr"><a
                                            href="mailto:keytruda@bayshore.ca">keytruda@bayshore.ca</a></span></span>
                            </li>

                            <li class="list-group-item"><span class="list_img"><img src="img/fax-icon.png" alt="fax"
                                        class="img-fluid"></span> <span class="program_ser_content"><span>Fax us:</span>
                                    <span class="contact_detail">1-855-549-9415</span></span></li>

                            <li class="list-group-item">
                                <div class="d-block enrollment_text">
                                    <p><b>MERCK Care™ Oncology Program Enrollment Form</b> <br> Fill out the form to
                                        enroll KEYTRUDA<sup>&reg;</sup> patients in the Merck Care™ Oncology Program:
                                    </p>
                                </div> <a href="img/oncology-form-en.pdf"
                                    class="btn button-primary text-capitalize download_now_btn" target="_blank"
                                    download>Download Now <img src="img/np_save.png" alt="download_icon"
                                        class="white-np"><img src="img/np-save-active.png" alt="download icon"
                                        class="active-np"></a>
                            </li>
                        </ul>
                        <!--end list group-->
                        <p class="merck_cana_text">™Merck Canada Inc.</p>
                    </div>
                    <!--end col6-->
                </div>
                <!--end row-->
            </div>
            <!--end container-->
        </section>
        <!--end page banner content section-->
        <!--section ends here-->

        <!--section starts here-->
        <section class="page-common-section w-100 view-merck second_view_merck">
            <div class="container py-5">

                <div class="row view_merck_row">
                    <div class="col-12 col-md-12 text-center view_merck_colum">
                        <h2 class="common-page-heading font-weight-bold text-white mb-4"> Learn more about
                            Keytruda<sup>&reg;</sup></h2>

                        <a class="btn button-primary button-white visit_button"
                            href="https://www.merckconnect.ca/en/products/keytruda/about.xhtml" target="_blank">Visit
                            Merck Connect <img src="img/visit_arrow.png" alt="arrow" class="arrow-blue"><img
                                src="img/button-white-arrow.png" alt="arrow" class="arrow-white"></a>
                    </div>
                    <!--end col-->
                </div>
                <!--end row-->

            </div>
            <!--end container-->
        </section>
        <!--end page banner content section-->
        <section class="footer_refrence_text">
            <div class="container">
                <p class="refre_top_text mt-4">AE=adverse event; ALK=anaplastic lymphoma kinase; AUC=area under the curve;
                    BICR=blinded independent central review; CI=confidence interval; ECOG PS= Eastern Cooperative
                    Oncology Group Performance Status, EGFR=epidermal growth factor receptor; HR=hazard ratio;
                    mNSCLC=metastatic non-small cell lung cancer; MRI=magnetic resonance imaging; ORR=objective response
                    rate; OS=overall survival; PD-L1 = programmed death ligand 1; PFS=progression-free survival;
                    plat/pem=cisplatin or carboplatin and pemetrexed; RECIST= Response Evaluation Criteria in Solid
                    Tumors; TPS=tumour proportion score</p>
                <div class="refrence_text">
                    <ul>
                        <li><strong>References:</strong></li>
                        <li>1. KEYTRUDA<sup>&reg;</sup> Product Monograph. Merck Canada Inc. April 18,
                            2019.</li>
                        <li>2. Gandhi L <i>et al.</i> Pembrolizumab plus chemotherapy in metastatic
                            non–small-cell lung cancer. <i>N Engl J Med</i> 2018; 378:2078-2092.</li>
                    </ul>
                    <ul>
                        <li>® Merck Sharp & Dohme Corp. Used under license.</li>
                        <li>© 2019 Merck Canada Inc. All rights reserved.</li>
                        <li>Merck Canada Inc.,</li>
                        <li>16750 Trans Canada Highway,</li>
                        <li>Kirkland, Quebec, Canada, H9H 4M7</li>
                        <li>Contact Us: <a href="mailto:medinfocanada@merck.com">medinfocanada@merck.com</a></li>
                    </ul>
                    <div class="refre_div">
                        <p class="refre_top_text pass_text">CA-KEY-OOO26</p>
                        <ul class="logo_list">
                            <li><img src="img/Keytruda-logo.png" alt="logo1"></li>
                            <li><img src="img/Merck-logo_std_CMYK.png" alt="logo2"></li>
                            <li><img src="img/Paab.png" alt="logo3"></li>
                            <li><img src="img/InnovativeMeds.png" alt="logo4"></li>
                        </ul>
                    </div>
                </div>

            </div>
        </section>
        <!--section ends here-->
    </main>
    <!--end site body-->
    <!--==========================site naub body starts here=====================================-->

    <!--==========================site footer starts here=====================================-->
    <footer class="footer" id="siteFooter">
        <div class="container">

            <div class="row">
                <div class="footer-list">
                    <ul class="footer-links list-inline">
                        <li class="list-inline-item"><a href="#section-1">KEYTRUDA<sup>&reg;</sup> Patient Profiles</a>
                        </li>
                        <li class="list-inline-item"><a href="#section-2">Efficacy</a></li>
                        <li class="list-inline-item"><a href="#section-3">Safety Profile</a></li>
                        <li class="list-inline-item"><a href="#section-4">Dosing</a></li>
                        <li class="list-inline-item"><a href="#section-5">Merck care<sup>TM</sup> Oncology Program</a>
                        </li>
                        <li class="list-inline-item"><a href="https://www.merck.ca/confirm-monograph.xhtml?file=KEYTRUDA-PM_E.pdf"
                                target="_blank">Product Monograph</a></li>

                        <li class="list-inline-item"><a href="#" data-toggle="modal" data-target="#safety-popup">Safety
                                Information</a></li>
                        <li class="list-inline-item"><a href="https://www.merck.ca/en/home/"
                                target="_blank">MERCK.CA</a></li>
                    </ul>
                    <!--end footer links-->

                    <div class="footer_contact_us">
                        <h3><b>Contact us:</b> <a href="mailto:medinfocanada@merck.com">medinfocanada@merck.com</a></h3>
                        <ul>
                            <li><a href="#" data-toggle="modal" data-target="#termuse-popup">Terms of Use</a></li>
                            <li><a href="https://www.merck.ca/en/privacy/" target="_blank"
                                    style="cursor:pointer;">Privacy policy</a></li>
                        </ul>
                    </div>
                </div>
                <!--end col 12-->
            </div>
            <!--end row-->
        </div>
        <!--end container-->

        <!-- safety popup-->

        <!-- The Modal -->
        <div class="modal popup-show" id="safety-popup">
            <div class="modal-dialog">
                <div class="modal-content">

                    <!-- Modal Header -->
                    <div class="modal-header">
                        <h4 class="modal-title">Safety information </h4>
                        <button type="button" class="close" data-dismiss="modal"><img
                                src="img/cross-white.png"></button>
                    </div>


                    <!-- Modal body -->
                    <div class="keytruda-background-content">
                        <h1>Keytruda<sup>®</sup></h1>
                        <h2>Safety Information</h2>
                    </div>
                    <div class="modal-body">
                        <div class="inner-modal-body">
                            <div class="uppper-use-sec">
                                
                                <div class="bor-accord-sec">
                                    <h3 class="green"><strong><u>Indication and clinical use:</u></strong> </h3>
                                    <p>KEYTRUDA<sup>®</sup> (pembrolizumab) has been issued marketing authorization without conditions for the treatment of patients with advanced or metastatic renal cell carcinoma in combination with axitinib, in adults with no prior systemic therapy for metastatic RCC. </p>
                                </div>
                               
                                <div class="rel-warning-sec">
                                    <h3 class="green"><strong><u>Relevant warnings and precautions: </u></strong> </h3>

                                   <ul class="nested-ul">
                                        <li>Immune-mediated adverse reactions, including severe and fatal cases:
                                            <ul>
                                                <li><span>Pneumonitis</span></li>
                                                <li><span>Colitis</span></li>
                                                <li><span>Hepatitis</span></li>
                                                <li><span>Nephritis and renal dysfunction</span></li>
                                                <li><span>Endocrinopathies including adrenal insufficiency (primary and secondary), hypophysitis, type 1 diabetes mellitus, and thyroid disorders</span></li>
                                                <li><span>Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis</span></li>
                                            </ul>
                                        </li>

                                    <li>Other immune-mediated adverse events, including uveitis, arthritis, myositis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (including exacerbation), vasculitis, Guillain-Barré syndrome, hemolytic anemia and pancreatitis</li>
                                    <li>Myocarditis</li>
                                    <li>Solid organ transplant rejection</li>
                                    <li>Elevated liver enzymes when KEYTRUDA® is given in combination with axitinib for RCC: Higher than expected frequencies of Grades 3 and 4 ALT and AST elevations have been reported in patients with advanced RCC. Monitor liver enzymes before initiation of, and periodically throughout, treatment. Consider more frequent monitoring of liver enzymes compared to when the drugs are used in monotherapy. Follow medical management guidelines for both drugs.</li>
                                    <li>Increased mortality in patients with multiple myeloma when KEYTRUDA<sup>®</sup> is added to a thalidomide analogue and dexamethasone</li>
                                    <li>Complications of allogenic hematopoietic stem cell transplant (HSCT) after treatment with KEYTRUDA<sup>®</sup> or if history of allogeneic HSCT prior to treatment with KEYTRUDA<sup>®</sup></li>
                                    <li>Severe infusion-related reactions, including hypersensitivity and anaphylaxis</li>
                                    <li>Embryofetal toxicity</li>
                                    <li>Not recommended in pregnant women</li>
                                    <li>In nursing women, a decision should be made whether to discontinue breast-feeding or KEYTRUDA<sup>®</sup> taking into account the benefit of breast-feeding for the child and the benefit of KEYTRUDA® therapy for the woman</li>
                                    <li>Has not been studied in patients with moderate or severe hepatic impairment</li>
                                    <li>Has not been studied in patients with severe renal impairment</li>
                                    <li>Monitor liver and thyroid function tests and electrolytes during treatment</li>
                                   </ul>
                                </div>

                                <div class="bottom-info-sec">
                                    <h3 class="green"><strong><u>For more information:</u> </strong></h3>
                                    <p>Please consult the KEYTRUDA<sup>®</sup> <a
                                            href="https://www.merck.ca/static/pdf/KEYTRUDA_PM_E.pdf"
                                            target="_blank">product monograph</a> for important information relating to adverse reactions, drug interactions and dosing information which have not been discussed in this piece.</p>
                                    <p>The product monograph is also available by calling <a
                                            href="tel:1-800-567-2594">1-800-567-2594</a>.</p>
                                </div>
                            </div>
                        </div>
                    </div>


                </div>
            </div>
        </div>
        <!-- safety popup-->

        <!-- The Modal -->
        <div class="modal" id="termuse-popup">
            <div class="modal-dialog">
                <div class="modal-content">

                    <!-- Modal Header -->
                    <div class="modal-header">
                        <h4 class="modal-title">TERMS OF USE EFFECTIVE AS OF MARCH 1, 2019 </h4>
                        <button type="button" class="close" data-dismiss="modal"><img
                                src="img/cross-white.png"></button>
                    </div>

                    <!-- Modal body -->
                    <div class="modal-body">
                        <div class="inner-modal-body">
                            <div class="uppper-use-sec">

                                <div class="bor-accord-sec">
                                    <p>PLEASE READ AND REVIEW THE FOLLOWING TERMS OF USE AGREEMENT CAREFULLY BEFORE
                                        USING THIS WEB SITE <a href="https://www.merck.ca/en/home/"
                                            target="_blank">(merck.ca)</a> (THE "Web Site") OWNED AND OPERATED BY MERCK
                                        CANADA INC., A SUBSIDIARY OF MERCK SHARP & DOHME CORP., KENILWORTH, NJ, USA
                                        ("Merck" or "Us"). By using this Web site, you agree to this Terms of Use
                                        Agreement. If you do not agree, please exit and disregard the information
                                        contained herein.</p>

                                    <p>This Web site is controlled and operated by Merck from Kirkland, Quebec and its
                                        content is designed to comply with Canadian laws and regulations. This site and
                                        these terms shall be governed by the laws of Quebec and the applicable laws of
                                        Canada without reference to principles of conflict of laws. You agree to be
                                        bound by such laws.</p>

                                    <p><strong>1. Acceptance.</strong> By using this Web site, you agree to be bound by
                                        and to comply with this Terms of Use Agreement. Merck reserves the right to
                                        change these terms from time to time, as it deems to be necessary. We will
                                        always post notice of those changes, and the date that they become effective,
                                        within the current Terms of Use Agreement on the Web site. You may view the
                                        current applicable version of this Terms of Use Agreement at any time through a
                                        link at the bottom of each page within this Web site.</p>

                                    <p><strong>2. Scope.</strong> The terms of use set forth in this agreement apply
                                        only to your use of this Web site. Merck operates other Web sites that are
                                        covered by their own conditions as specified within those Web sites.</p>

                                    <p><strong>3. Medical Information/Conditions.</strong> While there may be
                                        information on this Web site related to certain medical conditions and their
                                        treatment, should a medical condition exist, promptly see your own physician or
                                        health care provider. We do not offer personalized medical diagnosis or
                                        patient-specific treatment advice. Indeed, only your doctor or other health care
                                        professional, as a learned intermediary, can provide medical advice and
                                        determine if a product described in this, or any, Web site is appropriate for
                                        you.</p>

                                    <p>PLEASE CONSULT WITH YOUR DOCTOR OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL
                                        BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS, OR ANY OTHER, WEB SITE.</p>


                                    <p><strong>4. Description of Services.</strong> This Web site contains material
                                        about Merck and its various initiatives and products. Certain sections of this
                                        Web site are intended for particular audiences including Merck's employees,
                                        customers and shareholders, as well as to members of the health care community
                                        and the general public. Please feel free to browse this Web site, as
                                        appropriate. Your access to and use of the information contained herein is
                                        subject to this Terms of Use Agreement and all applicable laws. By accessing and
                                        browsing this Web site, you accept, without limitation or qualification, this
                                        Terms of Use Agreement and acknowledge that it supersedes any other agreement
                                        between you and Merck.</p>

                                    <p><strong>5. Ownership.</strong> Material on this Web site, including but not
                                        limited to text, images, illustrations, software, audio clips and video clips,
                                        is owned or otherwise provided by Merck, and Merck does not represent or warrant
                                        that such material does not infringe the rights of any other person or entity.
                                        Trademarks and logos (collectively, "Marks") displayed on this Web site are
                                        registered or unregistered Marks of Merck or others, are the property of their
                                        respective owners, and may not be used without written permission of Merck or of
                                        the owner of such Marks respectively. Any information or material contained on
                                        this Web site which may be reproduced pursuant to these terms must bear the
                                        proprietary rights notices which originally appear on or in conjunction with
                                        such information or material.</p>

                                    <p><strong>6. Representation.</strong> As a user of this Web site, you are liable
                                        for the accuracy of the information that you provide to us, including, but not
                                        limited to, your professional license number and your professional
                                        representation, if applicable.</p>

                                    <p>Should you respond with information including feedback or data such as questions,
                                        comments, suggestions, or the like regarding the content of this Web site, such
                                        information shall be deemed to be non-confidential, unless as may be required
                                        under applicable law, and Merck shall have no obligation of any kind with
                                        respect to such information and shall be free to reproduce, use, disclose, and
                                        distribute the information to others without limitation. You also warrant that
                                        any information or material including ideas, concepts, know-how or
                                        techniques contained in this information which you provide to Merck
                                        electronically through your access to or usage of this website does not infringe
                                        the rights of any person or entity. Merck shall be free to use any ideas,
                                        concepts, know-how or techniques contained in such information for any purpose
                                        whatsoever including but not limited to developing, manufacturing, and marketing
                                        products incorporating such information.</p>

                                    <p><strong>7. Privacy.</strong> Please refer to <a
                                            href="https://www.merck.ca/en/privacy/" target="_blank">Our Commitment to
                                            Privacy</a> for information on how the company protects your personal
                                        information.</p>

                                    <p><strong>8. Third Party Content and Links to Other Web sites.</strong> This Web
                                        site or other Merck Internet Web sites to which this Web Site links may contain
                                        information brought to you by third parties. This Web site may also provide
                                        links to other Internet websites. Merck assumes no responsibility for
                                        information provided by third parties or the content of other web sites to which
                                        Merck provides links. Merck does not review or control the content of any
                                        non-Merck site. Merck does not endorse and is not responsible for the accuracy,
                                        content, practice of standards of any non-Merck sources. Any links to other
                                        sites are provided merely as a convenience to the users of this Web site. Those
                                        Internet web sites are governed by their own terms of use displayed on the
                                        respective web sites.</p>

                                    <p><strong>9. Disclaimer of Warranties and Limitation of Liability.</strong> Merck
                                        has taken reasonable measures to ensure that the information contained within
                                        this Web site is reliable; however, by using this Web site, you accept the
                                        information, products and services provided herein "AS IS." Merck makes no
                                        express or implied warranty regarding the accuracy, content, completeness,
                                        reliability, operability, or legality of this Web Site and/or of information
                                        contained within this Web site. Merck exerts reasonable efforts to provide a
                                        satisfactory service, but we do not warrant that the Web Site will be accessible
                                        at any time without interruption, that it will be free of errors, breakdowns,
                                        failures, any harmful or damaging content or that it will be secure or protected
                                        from unauthorized access.</p>

                                    <p>Merck may not, under any circumstances, be held responsible for any damage, loss,
                                        costs or expenses directly or indirectly related to the access or use of this
                                        Web site and/or its content.</p>

                                    <p><strong>10. Consequences.</strong> If your violation of the Terms of Use
                                        Agreement causes harm to others, you agree to indemnify and hold Merck harmless
                                        from and against any and all loss, damage, or expense. If any dispute arises
                                        between us regarding this Agreement or your use of this Web site, it shall be
                                        resolved through good faith negotiations between the parties. If such efforts
                                        prove unsuccessful, all such controversies, claims, or disputes shall be
                                        submitted to the jurisdiction of the courts of Quebec.</p>


                                </div>
                            </div>
                        </div>
                    </div>


                </div>
            </div>
        </div>
        <!-- safety popup-->

    </footer>
    <!--end site footer-->
    <!--==========================site footer starts here=====================================-->


    <!-- External JavaScript goes here-->
    <script src="js/bootstrap.bundle.min.js"></script>
    <script src="js/slick.min.js"></script>

    <script src="js/jQuery-inView.min.js"></script>

    <!--custom js-->
    <script src="js/main.js"></script>


   <script>
        var navHeight = $('header#siteHeader').height();
        var navHeightnew = $('header#siteHeader').height() + 20;
        $('a.nav-link').on('click', function () {

            var $el = $(this)
                , id = $el.attr('href');

            jQuery("body, html").animate({
                scrollTop: jQuery(id).offset().top - navHeight
            }, 10);
            return false;

        });
        var scrollLink = $('.scroll');
        $(window).scroll(function () {

            var scrollbarLocation = $(this).scrollTop();
            scrollLink.each(function () {

                var sectionOffset = $(this.hash).offset().top - navHeightnew;

                if (sectionOffset <= scrollbarLocation) {
                    $('a.nav-link').removeClass('active');
                    $(this).addClass('active');
                    /*   $(this).siblings().removeClass('active');*/
                }
            })

        });
    </script>
</body>

</html>